Abstract:Although the risk difference (RD) is the most common and well explored functional form for testing efficacy with dichotomous endpoint, odds ratio (OR) is also suggested and well applied measure for non-inferiority (NI) trials. Since the construction and interpretation of these function forms are quite different, this study aims to provide detailed discussions and comprehensive comparisons on the design and testing approach for RD and OR scales for the fixed and group sequential three-arm NI trials under various of situations. The sample size determinations and testing approaches for assessing NI of a new treatment in three-arm clinical trials for RD and OR scales were reviewed comprehensively. Simulation studies are conducted for hundreds of scenarios with parameter configurations of the response rates, randomized allocations, NI margins and interim analysis. The operating characteristic (OC) of RD and OR scales based on the MLE and RMLE methods were thoroughly investigated. A trial example was designed and analyzed to demonstrate the methodologies. It is found that sample size determination on OR scale gives smaller sample size and robust procedure compared to RD scale in the majority of situations. When evaluating the behaviors of the attained power, the RMLE methods based on OR scale outperforms the MLE method and tend to have more power to reject the null hypothesis especially under the small sample size situations. Compared to the fixed design, the group sequential design has better OC, which provides a comparable power while needing smaller total average sample sizes for all cases. In addition, we suggest a lower significance level with a higher power for the sample size determination in the superiority test stage in the group sequential design, which can significantly reduce the total sample sizes while the number of subjects in the placebo group does not increase much. It can offer some recommendations for the investigators to choose the optimal endpoints and parameter configurations to design a three-arm NI trial under certain situations.

Sample size estimation and statistical inference in noninferiority/equivalence trials

Testing two variances for superiority/non-inferiority and equivalence: Using the exhaustion algorithm for sample size allocation with cost

The Non-Inferiority Test in the Research of Methodology and the Experiment of Comparison

On sample size calculation based on odds ratio in clinical trials.

On Sample Size Calculation in Bioequivalence Trials

Dealing with Non-inferiority Test in Multicenter Trials

A Note on Sample Size Calculation for Mean Comparisons Based on Noncentral T-Statistics.

Unconditional Exact Tests for Equivalence or Noninferiority for Paired Binary Endpoints

Sample Size Estimation in the Sequential Parallel Comparison Design and the Two-way Enriched Design

A Direct Approach to Simultaneous Tests of Superiority and Noninferiority with Multiple Endpoints

Optimization the Design of Fixed and Group Sequential Three-Arm Non-Inferiority Trials with Dichotomous Endpoints of Risk Difference and Odds Ratio

Systematic Evaluation of Non-Inferiority and Equivalence Randomized Trials of Anti-Infective Drugs

Optimal sample size allocation for two‐arm superiority and non‐inferiority trials with binary endpoints

Some Statistical Issues of Confirming Efficacy in Clinical Trials

An improved sample size calculation method for score tests in generalized linear models

Wald tests for variance-adjusted equivalence assessment with normal endpoints

Equivalence Test for Cross-over Clinical Trial

A Simple Formula for Sample Size Calculation in Equivalence Studies

A Sample Size Planning Approach That Considers Both Statistical Significance and Clinical Significance

Impact of Sample Size and Variability on the Power and Type I Error Rates of Equivalence Tests: A Simulation Study.

The Comparison Research between Chinese Guideline of Statistical Principles in Clinical Trials and ICH E9